User:Kelgee/sandbox
Adult T-cell leukemia/lymphoma (ATL or ATLL) is a rare
Current treatment regiments for ATL are based on clinical subtype and response to initial therapy. Some therapy modalities for treatment may not available in all countries therefore strategies differ across the world. All patients are referred to clinical trials if available. Beyond clinical trials, treatments are centered on multiagent chemotherapy, zidovudine plus interferon a (AZT/IFN), and allogenic hematopoietic stem cell transplantation (alloHSCT). [2]
Globally, the retrovirus HTLV-1 is estimated to infect 20 million people with the incidence of ATL approximately 0.05 per 100,000 with endemic regions such as regions of Japan, as high as 27 per 100,000. However, cases have increased in non-endemic regions with highest incidence of HTLV-1 in southern/northern islands of Japan, Caribbean, Central and South America, intertropical Africa, Romania, northern Iran. ATL normally occurs around the age of 62 years but median age at diagnosis does depend on prevalence of the HTLV-1 infection in the geographic location. [3]
Contents
- 1Signs and symptoms
- 2Transmission
- 3Diagnosis
- 4Treatment
- 5Epidemiology
- 6Research
- 7References
- 8Further reading
- 9External links
Signs and symptoms[edit]
ATL is a rare aggressive peripheral T- cell neoplasm that is associated with HTLV-1.
Infection with HTLV-1, like infection with other
Transmission
Transmission of
Diagnosis
Diagnosis is made based on the combination of clinical features, characteristic morphologic and immunophenotypic changes of malignant cells. As clinical features and prognosis can be diverse, the disease is subtype-classified into four categories according to the Shimoyama classification: acute, lymphoma, chronic, smoldering. [5] Normally, identification of at least 5 percent of tumor cells in peripheral blood and confirmation of human T-lymphotropic virus type-1 are sufficient for diagnosis of acute, chronic, and smoldering types. For the lymphoma type, histopathologic examination by biopsy of lymph nodes may be needed. [6]
Multilobed nuclei that are "flower-like" or cerebriform in appearance in flow cytometry support diagnosis of ATL. Additionally, detection of HTLV-1 by ELISA and western blot confirmation is essential for diagnosis. Genomic changes are complex therefore, there is no single characteristic marker to contribute to diagnosis. [2]
Due to variable clinical course, patients are classified by the Shimoyama Classification into different subtypes of ATL. Categorization is based on cell counts, LDH levels, calcium levels and sites of organ involvement.[7]
Treatment:
Multi agent chemotherapy options include follow combination
VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, and prednisone; doxorubicin, ranimustine, and prednisolone; and vindesine, etoposide, carboplatin, and prednisolone); CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisolone); etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin (EPOCH); CHOEP (cyclophosphamide, vincristine, doxorubicin, etoposide, and prednisolone); dose-adjusted EPOCH; or hyper CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine) [8][9][10]
2/3 - Epidemiology of disease
4- genetic pathophysiology, low incidence of HTLV infected individuals to malignancy, gene sequencing (Kataoka)
2- 2009 guidelines and 2019 updates(cook)
ishida- combination chemo with mogamulizumab, phase 2 clinical trial
Ishitsuka- treatment
Matutes/ Hermine - AZT + IFN-a treatment effectiveness
Chihara - epidemiology of ATLL
Ishida/uike - mogalizumab approved in 2012
Phillips - brentuximab
Bibliography
- ISSN 1474-175X.
- ^ PMID 30047026.
- ^ a b Cite error: The named reference
:0
was invoked but never defined (see the help page). - ^ Gotuzzo E, Verdonck K. "HTLV-1: CLINICAL IMPACT OF A CHRONIC INFECTION". NCBI. Retrieved 22 July 2013.
- ISSN 1607-8454.
- ISSN 1365-2141.
- ISSN 0007-1048.)
{{cite journal}}
: CS1 maint: date format (link - ISSN 1540-1405.
- ISSN 1365-2141.
- ISSN 0732-183X.
[1][2][3][4][5][6][7][8][9][10][11]